期刊文献+

测定人血浆中巴洛沙星浓度的反相高效液相色谱荧光法

Determination of balofloxacin in human plasma by RP-HPLC with fluorescence detection
暂未订购
导出
摘要 目的建立反相高效液相色谱荧光法测定人血浆中巴洛沙星浓度。方法采用Diamonsil ODS C_(18)分析柱(200 mm×4.6 mm,5μm),柱温为室温,流动相为乙腈-0.05 mol·L^(-1)KH_2PO_4缓冲液(25:75,V/V)(三乙胺和H_3PO_4调pH为3.40),流速:1.0 mL·min^(-1);血浆样品用二氯甲烷旋涡混合后,提取有机层,在40℃条件下氮气吹干,残渣用流动相溶解进样,荧光检测器(λ_(cx)=295 nm,λ_(cm)500 nm)检测,以加替沙星作内标,按内标法定量。结果标准曲线在50~4 000μg·L^(-1)内线性良好,最低检测限为10μg·L^(-1),巴洛沙星及内标的保留时间分别为5.35和4.03 min,日内和日间RSD均<10.0%,提取回收率和方法回收率分别在92%~99%和95%~105%。结论本法具有快速、简便、灵敏、准确等优点,适用于人血浆中巴洛沙星浓度测定及药动学研究。 AIM To establish an RP-HPLC method with fluorescence detection for the determination of balofloxacin in human plasma. METHODS A fluorescence detector and Diamonsil ODS ClS analysis column (200 mm × 4.6 mm,5 μm) were used.The plasma sample was extracted with 4.0 mL dichloromethane.After evaporation of the organic layer, the residue was dissolved in 200 μL mobile phase and 20 μL was injected into the column. The mobile phase of acetonitril-0.05 mol· L^-1 potassium dihydrogen phosphate (25:75, V/V) was eluted at flow rate of 1.0 mol· L^-1 through the column. The detector at high sensitivity was set at λ ex 295 nm and λ ex 500 ran. RESULTS The retention time for balofloxacin and intemal standard (gatifloxacin) was 5.35 rain and 4.03 min, respectively. The standard curve was linear over the concentration range of 50 to 4 000 μg· L^- 1. The lowest concentration of detection in plasma was 10 μg· L^- 1 .The extraction recoveries and method recoveries were 92% - 99% and 95% - 105%, respectively. The intra-day RSD and inter-day RSD were less than 10%. CONCLUSION This method is simple, rapid, sensitive and accurate and suitable for clinical practical application.
出处 《中国临床药学杂志》 CAS 2007年第5期296-299,共4页 Chinese Journal of Clinical Pharmacy
关键词 巴洛沙星 血药浓度 反相高效液相色谱 balofloxacin plasma drug concentration RP-HPLC
  • 相关文献

参考文献5

二级参考文献31

  • 1刘明亮,刘秉全,孙兰英,郭慧元.巴洛沙星的合成[J].中国医药工业杂志,2004,35(7):385-388. 被引量:18
  • 2夏建民.抗菌新药普利沙星[J].上海医药,1996(11):24-24. 被引量:7
  • 3.中国药典[M].,2000..
  • 4Alksne L. Balofloxacin choongwae[J]. Curt Opin Investig Drugs,2003,4(2) : 224 - 229.
  • 5Ochi. K. Process for producing quinolonecarboxylic acid derivative[ P] . EP,0641782A1 , 1992 - 07 - 15.
  • 6Takagi N, Fubasami H, Matsukubo H. (6,7)-substituted-8-aikoxy-1-cyclo-propyl-1, 4ihydro-4-oxo-3-quinoline-carboxylic acid-( 03,04)-bis(acyloxy-0) borate and the salt thereof, and the preparing method of the same[P]. USP,5157117, 1992- 10- 20.
  • 7Nagano H, Yokota T, Katoh Y. Novel quinolonecarboxylic acid derrivatives[ P]. USP,5051509,1991 - 09 - 24.
  • 8永野洋幸,横田 健,加藤保幸.新规キノロソカルボソ酸誘導体[P].平3—95117,1991—04—19.
  • 9Kojima K, Ito T, Munemura K, et al. In vitro antibacterial activity of balofloxacin[J]. Jpn J Chemother, 1995,43 (S5) : S60 - S76.
  • 10Kojima K, Ito T, Munemura K, et al. In vivo antibacterial activity of balofloxacin[J]. Jpn J Chemother, 1995,43(S5) :S77 - S83.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部